These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 25990504)
1. VEGF111b, a C-terminal splice variant of VEGF-A and induced by mitomycin C, inhibits ovarian cancer growth. Li X; Gu F; Niu C; Wang Y; Liu Z; Li N; Pan B; He D; Kong J; Zhang S; Wang X; Yao Y; Zheng L J Transl Med; 2015 May; 13():164. PubMed ID: 25990504 [TBL] [Abstract][Full Text] [Related]
2. VEGF111b, a new member of VEGFxxxb isoforms and induced by mitomycin C, inhibits angiogenesis. Gu F; Li X; Kong J; Pan B; Sun M; Zheng L; Yao Y Biochem Biophys Res Commun; 2013 Nov; 441(1):18-24. PubMed ID: 24125722 [TBL] [Abstract][Full Text] [Related]
4. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Rennel E; Waine E; Guan H; Schüler Y; Leenders W; Woolard J; Sugiono M; Gillatt D; Kleinerman E; Bates D; Harper S Br J Cancer; 2008 Apr; 98(7):1250-7. PubMed ID: 18349828 [TBL] [Abstract][Full Text] [Related]
5. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. Nowak DG; Woolard J; Amin EM; Konopatskaya O; Saleem MA; Churchill AJ; Ladomery MR; Harper SJ; Bates DO J Cell Sci; 2008 Oct; 121(Pt 20):3487-95. PubMed ID: 18843117 [TBL] [Abstract][Full Text] [Related]
6. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways. Gao F; Vasquez SX; Su F; Roberts S; Shah N; Grijalva V; Imaizumi S; Chattopadhyay A; Ganapathy E; Meriwether D; Johnston B; Anantharamaiah GM; Navab M; Fogelman AM; Reddy ST; Farias-Eisner R Integr Biol (Camb); 2011 Apr; 3(4):479-89. PubMed ID: 21283904 [TBL] [Abstract][Full Text] [Related]
7. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies. Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G Oncotarget; 2017 Feb; 8(6):9174-9188. PubMed ID: 27999187 [TBL] [Abstract][Full Text] [Related]
8. Comparative insight into expression of recombinant human VEGF111b, a newly identified anti-angiogenic isoform, in eukaryotic cell lines. Dehghanian F; Hojati Z Gene; 2014 Dec; 553(1):57-62. PubMed ID: 25284510 [TBL] [Abstract][Full Text] [Related]
9. Integrin alpha x stimulates cancer angiogenesis through PI3K/Akt signaling-mediated VEGFR2/VEGF-A overexpression in blood vessel endothelial cells. Wang J; Yang L; Liang F; Chen Y; Yang G J Cell Biochem; 2019 Feb; 120(2):1807-1818. PubMed ID: 30873824 [TBL] [Abstract][Full Text] [Related]
10. The inhibitory effect of doxycycline on cisplatin-sensitive and -resistant epithelial ovarian cancer. Wu W; Yu LH; Ma B; Xu MJ PLoS One; 2014; 9(3):e89841. PubMed ID: 24598933 [TBL] [Abstract][Full Text] [Related]
11. VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation. Shathasivam P; Kollara A; Spybey T; Park S; Clarke B; Ringuette MJ; Brown TJ Br J Cancer; 2017 Apr; 116(8):1065-1076. PubMed ID: 28301874 [TBL] [Abstract][Full Text] [Related]
12. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways. Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174 [TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling. Huang SW; Lien JC; Kuo SC; Huang TF Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611 [TBL] [Abstract][Full Text] [Related]
14. The antihypertension drug doxazosin inhibits tumor growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling and VEGF and HIF-1α expression. Park MS; Kim BR; Dong SM; Lee SH; Kim DY; Rho SB Oncotarget; 2014 Jul; 5(13):4935-44. PubMed ID: 24952732 [TBL] [Abstract][Full Text] [Related]
15. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model. Ding C; Li L; Yang T; Fan X; Wu G BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of Ca Liu Z; Zhang S; Hou F; Zhang C; Gao J; Wang K Int J Cancer; 2019 May; 144(9):2215-2226. PubMed ID: 30243029 [TBL] [Abstract][Full Text] [Related]
17. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer. Shao M; Hollar S; Chambliss D; Schmitt J; Emerson R; Chelladurai B; Perkins S; Ivan M; Matei D Mol Cancer Ther; 2012 Jul; 11(7):1576-86. PubMed ID: 22700681 [TBL] [Abstract][Full Text] [Related]
18. sMEK1 inhibits endothelial cell proliferation by attenuating VEGFR-2-dependent-Akt/eNOS/HIF-1α signaling pathways. Kim BR; Seo SH; Park MS; Lee SH; Kwon Y; Rho SB Oncotarget; 2015 Oct; 6(31):31830-43. PubMed ID: 26378810 [TBL] [Abstract][Full Text] [Related]
19. New prospects in the roles of the C-terminal domains of VEGF-A and their cooperation for ligand binding, cellular signaling and vessels formation. Delcombel R; Janssen L; Vassy R; Gammons M; Haddad O; Richard B; Letourneur D; Bates D; Hendricks C; Waltenberger J; Starzec A; Sounni NE; Noël A; Deroanne C; Lambert C; Colige A Angiogenesis; 2013 Apr; 16(2):353-71. PubMed ID: 23254820 [TBL] [Abstract][Full Text] [Related]
20. FAM83D inhibits autophagy and promotes proliferation and invasion of ovarian cancer cells via PI3K/AKT/mTOR pathway. Zhu H; Diao S; Lim V; Hu L; Hu J Acta Biochim Biophys Sin (Shanghai); 2019 May; 51(5):509-516. PubMed ID: 30939187 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]